← back to search

Núria Montserrat

Institució Catalana de Recerca i Estudis Avançats ·
Area of research
Molecular Biology · Surgery
Research interest
Research interests include Pluripotent Stem Cells Research, CRISPR and Genetic Engineering, Renal and related cancers, and Tissue Engineering and Regenerative Medicine.
h-index
50
citations
11,807
works
158
NIH funding
primary concept
Biology
email

Recent publications

Systematic production of human kidney organoids for transplantation in porcine kidneys during ex vivo machine perfusion
Nature Biomedical Engineering 2025cited by 7position: lastdoi
Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo
Cell stem cell 2024cited by 34position: middledoi
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
Cell Metabolism 2022cited by 112position: lastdoi
ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology
eLife 2022cited by 66position: middledoi
Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants
EMBO Molecular Medicine 2022cited by 52position: middledoi
Principles for the design of multicellular engineered living systems
APL Bioengineering 2022cited by 48position: middledoi
Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity
Cell 2022cited by 27position: middledoi
Protocol for SARS-CoV-2 infection of kidney organoids derived from human pluripotent stem cells
STAR Protocols 2022cited by 2position: lastdoi
ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update
Stem Cell Reports 2021cited by 339position: middledoi
Genome-wide spatial expression profiling in formalin-fixed tissues
Cell Genomics 2021cited by 116position: middledoi
The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses
Microorganisms 2021cited by 33position: middledoi
A diabetic <i>milieu</i> increases cellular susceptibility to SARS-CoV-2 infections in engineered human kidney organoids and diabetic patients
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 2position: lastdoi
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
Cell 2020cited by 2,259position: middledoi
Human recombinant soluble ACE2 in severe COVID-19
The Lancet Respiratory Medicine 2020cited by 428position: middledoi
Rethinking organoid technology through bioengineering
Nature Materials 2020cited by 316position: lastdoi
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
EMBO Molecular Medicine 2020cited by 106position: middledoi
Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases
Nature Cell Biology 2020cited by 65position: middledoi
The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting
Transplant International 2020cited by 24position: middledoi
Active superelasticity in three-dimensional epithelia of controlled shape
Nature 2018cited by 353position: middledoi
Forty years of IVF
Fertility and Sterility 2018cited by 296position: middledoi
Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing
Cell 2015cited by 285position: middledoi
Analysis of protein-coding mutations in hiPSCs and their possible role during somatic cell reprogramming
Nature Communications 2013cited by 70position: middledoi
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2
Nature 2012cited by 340position: middledoi
Identification of a specific reprogramming-associated epigenetic signature in human induced pluripotent stem cells
Proceedings of the National Academy of Sciences 2012cited by 171position: middledoi
Conversion of human fibroblasts to angioblast-like progenitor cells
Nature Methods 2012cited by 149position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alì Mirazimi · Public Health Agency of Sweden9 papers (2020–2022)Josef Penninger · Helmholtz Centre for Infection Research8 papers (2020–2022)Elena Garreta · Barcelona Institute of Science and Technology6 papers (2018–2022)Vanessa Monteil · Public Health Agency of Sweden6 papers (2020–2022)Juan Carlos Izpisúa Belmonte · Alto Neuroscience (United States)5 papers (2012–2015)Astrid Hagelkrüys · Medical University of Vienna4 papers (2020–2022)Sergio Ruiz · Center for Cancer Research4 papers (2012–2013)Haibo Zhang · Guangzhou University of Chinese Medicine4 papers (2020–2021)Ignacio Sancho-Martinez · Salk Institute for Biological Studies3 papers (2012–2015)Arthur S. Slutsky · Toronto Rehabilitation Institute3 papers (2020–2020)Carmen Hurtado del Pozo · Breakthrough3 papers (2020–2021)Gerald Wirnsberger · Medical University of Graz3 papers (2020–2022)Patricia Prado · Institute for Bioengineering of Catalonia3 papers (2020–2022)Xavier Trepat · Institut Pasteur2 papers (2018–2020)Concepción Rodrı́guez Esteban · Salk Institute for Biological Studies2 papers (2012–2015)Erika M. Batchelder · Salk Institute for Biological Studies2 papers (2012–2013) · 2 papers (2021–2022)Josep M. Campistol · Hospital Clínic de Barcelona2 papers (2015–2021)Emmanuel Nivet · Centre National de la Recherche Scientifique2 papers (2012–2012) · 2 papers (2021–2022)